Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Swain

Showing results (461-470 of 532) with videos related to

Pageof 54
Sort By:
Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.
Breast Cancer Research and Treatment|September 20, 2022
Molecular characterization of ESR1 variants in breast cancerArielle L Heeke, Andrew Elliott, Rebecca Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Nature Communications|December 13, 2023
Grassland intensification effects cascade to alter multifunctionality of wetlands within metaecosystemsYuxi Guo, Elizabeth H Boughton, Stephanie Bohlman, et al.
Gene Therapy|November 20, 2015
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibilityP-Y Wang, H M Swain, A L Kunkler, et al.
Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of the National Cancer Institute|February 16, 2026
Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse eventsRakchha Chhetri, Natansh D Modi, Bradley D Menz, et al.
Aging Cell|October 2, 2024
Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19Rodrigo J Valderrábano, Benjamin Wipper, Karol Mateusz Pencina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
Pageof 54

Showing results (461-470 of 532) with videos related to

Sort By:
Pageof 54
Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.
Breast Cancer Research and Treatment|September 20, 2022
Molecular characterization of ESR1 variants in breast cancerArielle L Heeke, Andrew Elliott, Rebecca Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Nature Communications|December 13, 2023
Grassland intensification effects cascade to alter multifunctionality of wetlands within metaecosystemsYuxi Guo, Elizabeth H Boughton, Stephanie Bohlman, et al.
Gene Therapy|November 20, 2015
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibilityP-Y Wang, H M Swain, A L Kunkler, et al.
Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of the National Cancer Institute|February 16, 2026
Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse eventsRakchha Chhetri, Natansh D Modi, Bradley D Menz, et al.
Aging Cell|October 2, 2024
Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19Rodrigo J Valderrábano, Benjamin Wipper, Karol Mateusz Pencina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
Pageof 54